שיתוף פעולה בין Fortrea ל-Omico לקידום פיתוח תרופות אונקולוגיות המבוססות על סמנים ביולוגיים

Fortrea, a leading global clinical research organization, has announced a collaboration with Omico, Australia's leading precision oncology platform, to accelerate biomarker-driven oncology research. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial design, site selection, and patient recruitment, enabling faster access to relevant clinical trials for cancer patients based on their genomic profiles across Australia.